At present, radiotherapy, chemotherapy and targeted drug therapy are the main treatment in clinic, however, many patients, such as KRAS-mutant NSCLC, are not response or resistant to chemotherapy and targeted drug therapy [2]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.